Business Wire

CA-RESOLVE-SYSTEMS

5.8.2020 09:02:09 CEST | Business Wire | Press release

Share
Cherwell Now Offers Automated Discovery and Dependency Mapping (DDM) Powered by Resolve Systems

Cherwell Software LLC, a leading provider of IT Service Management (ITSM) and Enterprise Service Management (ESM) solutions, joins forces with Resolve Systems , a leader in enterprise automation and AIOps, to help companies better manage their complex IT environments through workflow automation and auto-discovery and dependency mapping. Cherwell is now an official reseller of Resolve products and can seamlessly deliver the integrated offering to their customers. Cherwell selected Resolve’s automated discovery and dependency mapping solution based on its robust capabilities and customer success.

The collaboration between Resolve and Cherwell provides a complete solution for streamlining IT operations and accelerating service delivery. Combining best-in-class ITSM and robust discovery and dependency mapping immediately provides customers deep visibility into complex, hybrid environments, while also forging a strong foundation to advance AIOps initiatives.

“By partnering with one of the leaders in enterprise service management and ITSM, we’re able to offer a comprehensive solution to automating IT operations and accelerating service desk transformation,” said Rob Kelsall, VP of Global Sales Engineering for Resolve. “We look forward to helping Cherwell customers achieve agile, autonomous operations, starting with automated discovery and dynamic dependency mapping.”

“As a fellow leader in the domain, we couldn’t be more pleased that Resolve is expanding their collaboration with us. Together, our goal is to offer exceptional, end-to-end solutions for the entire enterprise,” said Scott Gainey, chief marketing officer of Cherwell.

By combining Resolve’s discovery and dependency mapping solution with Cherwell ITSM, customers can:

  • Eliminate manual work by automating discovery and real-time updates to their Cherwell CMDB
  • Identify and track dynamic, multi-layer relationships between applications and hybrid infrastructure
  • Auto-generate complex topology maps to visualize infrastructure relationships and facilitate troubleshooting

Resolve integrates seamlessly with Cherwell’s flagship offering, Cherwell Service Management — delivered on Cherwell's powerful and flexible no-code CORE™ platform. Cherwell enables IT, HR, Facilities, and other teams to implement, automate and modernize service and support processes to meet new and evolving needs — at a fraction of the cost and complexity of other tools.

Resolve’s discovery and dependency mapping product is part of their comprehensive automation and AIOps platform, which is integrated with Cherwell’s IT Service Management® solution. Resolve provides full-stack visibility into complex, hybrid IT environments by performing agentless auto-discovery of all physical and virtual entities, mapping dependencies, and creating topology maps that enable IT teams to see what they are managing. This integration can be found on the Cherwell Marketplace .

To learn more about Cherwell’s new discovery and dependency mapping, powered by Resolve, visit cherwell.com/products/it-service-management/discovery-and-dependency-mapping/ .

About Cherwell

Cherwell (@Cherwell) empowers organizations to transform their business through the rapid adoption and easy management of digital services. Cherwell’s adaptable platform has enabled thousands of organizations to modernize their business operations with customizable service management, automation, and reporting across the enterprise. For more information, visit: https://www.cherwell.com .

About Resolve Systems

Resolve helps IT teams achieve agile, autonomous operations with an industry-leading, enterprise automation and AIOps platform. By combining insights from artificial intelligence with powerful, cross-domain automation, Resolve handles a wide array of IT operations – from dependency mapping, event correlation, and predictive analytics to intelligently automating actions based on those findings. Purpose-built to address challenges posed by increasing IT complexity, Resolve enables organizations to maximize operational efficiency, reduce costs, quickly troubleshoot and fix problems, and accelerate service delivery. See why the Fortune 1000, leading MSPs, and the largest communication service providers on the planet trust Resolve to power millions of automations every day. Learn more at resolve.io or follow us on Twitter @ResolveSystems .

Social Media:

https://www.facebook.com/ResolveSoftwareSystem

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye